Literature DB >> 26250576

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

Nathan H Fowler1, Loretta J Nastoupil2, Frederick B Hagemeister2, Sattva S Neelapu2, Luis E Fayad2, Denise LeBlanc2, Felipe Samaniego2, Chan Yoon Cheah2.   

Abstract

Entities:  

Keywords:  lenalidomide; non-Hodgkin lymphoma; rash; rituximab

Mesh：

Substances：

Year:  2015        PMID： 26250576      PMCID： PMC4825296          DOI： 10.3324/haematol.2015.131144

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

2.  Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.

Authors:  Thomas E Witzig; Allen M Vukov; Thomas M Habermann; Susan Geyer; Paul J Kurtin; William R Friedenberg; William L White; Haji I Chalchal; Patrick J Flynn; Thomas R Fitch; Debra A Welker
Journal:  J Clin Oncol       Date:  2005-01-18       Impact factor: 44.544

3.  Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.

Authors:  M Wang; N Fowler; N Wagner-Bartak; L Feng; J Romaguera; S S Neelapu; F Hagemeister; M Fanale; Y Oki; B Pro; J Shah; S Thomas; A Younes; C Hosing; L Zhang; K J Newberry; M Desai; N Cheng; M Badillo; M Bejarano; Y Chen; K H Young; R Champlin; L Kwak; L Fayad
Journal:  Leukemia       Date:  2013-04-02       Impact factor: 11.528

Review 4.  A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

Authors:  T E Witzig; G S Nowakowski; T M Habermann; A Goy; F J Hernandez-Ilizaliturri; A Chiappella; U Vitolo; N Fowler; M S Czuczman
Journal:  Ann Oncol       Date:  2015-02-23       Impact factor: 32.976

5.  Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

Authors:  Michael Wang; Luis Fayad; Nicolaus Wagner-Bartak; Liang Zhang; Fredrick Hagemeister; Sattva S Neelapu; Felipe Samaniego; Peter McLaughlin; Michelle Fanale; Anas Younes; Fernando Cabanillas; Nathan Fowler; Kate J Newberry; Luhong Sun; Ken H Young; Richard Champlin; Larry Kwak; Lei Feng; Maria Badillo; Maria Bejarano; Kimberly Hartig; Wendy Chen; Yiming Chen; Catriona Byrne; Neda Bell; Jerome Zeldis; Jorge Romaguera
Journal:  Lancet Oncol       Date:  2012-06-06       Impact factor: 41.316

6.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

Authors:  J O Armitage; D D Weisenburger
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

7.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Authors:  P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

Review 8.  Non-Hodgkin lymphoma.

Authors:  Kate R Shankland; James O Armitage; Barry W Hancock
Journal:  Lancet       Date:  2012-07-25       Impact factor: 79.321

9.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Authors:  Peter H Wiernik; Izidore S Lossos; Joseph M Tuscano; Glen Justice; Julie M Vose; Craig E Cole; Wendy Lam; Kyle McBride; Kenton Wride; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Thomas M Habermann
Journal:  J Clin Oncol       Date:  2008-07-07       Impact factor: 44.544

10.  Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Authors:  Thomas E Witzig; Peter H Wiernik; Timothy Moore; Craig Reeder; Craig Cole; Glen Justice; Henry Kaplan; Michael Voralia; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Julie M Vose
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544
View more
  1 in total

Review 1.  Underlying mechanisms and drug intervention strategies for the tumour microenvironment.

Authors:  Haoze Li; Lihong Zhou; Jing Zhou; Qi Li; Qing Ji
Journal:  J Exp Clin Cancer Res       Date:  2021-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.